Phase I trial of imexon in patients with advanced malignancy

Journal of Clinical Oncology

Volumn 25, Issue 13, 2007, Pages 1779-1784

  Dragovich, Tomislav ^a   Gordon, Michael ^a   Mendelson, David ^a   Wong, Lucas ^a   Modiano, Manuel ^a   Chow, H H Sherry ^a   Samulitis, Betty ^a   O'Day, Steven ^a   Grenier, Kathryn ^a   Hersh, Evan ^a   Dorr, Robert ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYSTINE; DOCUSATE SODIUM; DOXORUBICIN; ELSAMICIN A; FLUDARABINE; GRANISETRON; IBRITUMOMAB TIUXETAN; IMEXON; MACROGOL 3350; NSC 714597; ONDANSETRON; PREDNISONE; REACTIVE OXYGEN METABOLITE; RITUXIMAB; SODIUM DIHYDROGEN PHOSPHATE; THIOL; UNCLASSIFIED DRUG; VINCRISTINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BACKACHE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; FEMALE; HALF-LIFE; HEXANONES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 33947309495     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.9672     Document Type: Article

References (25)

1. Iyengar BS, Dorr RT, Remers WA: Chemical basis for the biological activity of imexon and related cyanoaziridines. J Med Chem 47:218-223, 2004
2. Dvorakova K, Payne CM, Tome ME, et al: Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 60:749-758, 2000
3. Dvorakova K, Waltmire CN, Payne CM, et al: Induction of mitochondrial changes in myeloma cells by imexon. Blood 97:3544-3551, 2001
4. Dvorakova K, Payne CM, Landowski TH, et al: Imexon activates an intrinsic apoptosis pathway in RPM18226 myeloma cells. Anticancer Drugs 13:1031-1042, 2002
5. Evens AM, Prachand S, Shi B, et al: Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. Clin Cancer Res 10:1481-1491, 2004
6. Samulitis BK, Landowski TH, Dorr RT: Correlates of imexon sensitivity in human multiple myeloma cell lines. Leuk Lymphoma 47:97-109, 2006
7. Dorr RT, Raymond MA, Landowski TH, et al: Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines. Int J Gastrointest Cancer 36:15-28, 2005
8. Bicker U: BM 06 002: A new immunostimulating compound, in Chirigos MA (ed): Immune Modulation and Control of Neoplasia by Adjuvant Therapy. New York, NY, Raven Press, 1978, pp 389-401
9. Micksche M, Kokoschka EM, Sagaster P, et al: Phase I study for a new immunostimulating drug, BM 06 002, in man, in Chirigos MA (ed): Immune Modulation and Control of Neoplasia by Adjuvant Therapy. New York, NY, Raven Press, 1978, pp 403-443
10. Salmon SE, Hersh EM: Sensitivity of multiple myeloma to imexon in the human tumor cloning assay. J Natl Cancer Inst 86:228-230, 1994
11. Funk CY, Eisman J, Hersh EM: Treatment of the murine, retrovirus-induced lymphoproliferative immunodeficiency disease (LP-BM5) in C57BL/10 mice with the immunomodulator imexon. AIDS Res Hum Retroviruses 8:633-638, 1992
12. Hersh EM, Gschwind CR, Taylor CW, et al: Anti-proliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst 84:1238-1244, 1992
13. Dorr RT, Little JD, Klein MK, et al: Preclinical pharmacokinetics and antitumor activity of imexon. Invest New Drugs 13:113-116, 1995
14. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
15. Therasse P, Arbuch SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
16. Jones DP, Carlson JL, Samiec PS, et al: Glutathione measurement in human plasma evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC. Clin Chim Acta 275:175-184, 1998
17. Woo SH, Park IC, Park MJ, et al: Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB activation. Int J Cancer 112:596-606, 2004
18. Evens AM, Lecane P, Magda D, et al: Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 105:1265-1273, 2005
19. Fribley A, Zeng Q, Wang C-Y: Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24:9695-9704, 2004
20. Pelicano H, Carney D, Haung P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7:97-110, 2004
21. Hodge DR, Peng B, Pompeia C, et al: Epigenetic silencing of manganese superoxide dismutase (SOD-2) in KAS 6/1 human multiple myeloma cells increases cell proliferation. Cancer Biol Ther 4:585-592, 2005
22. Scott J, Dorr RT, Samulitis B, et al: Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol
23. Pourpak A, Meyers RO, Samulitis BK, et al: Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anticancer Drugs 17:1179-1184, 2006
24. Rimaniol AC, Mialocq P, Clayette P, et al: Role of glutamate transporters in the regulation of glutathione levels in human macrophages. Am J Physiol Cell Physiol 281:C1964-C1970, 2001
25. Thoene JG: Cystinosis. J Inherit Metab Dis 18:380-386, 1995